Understand how targeted therapy is diagnosed and staged at Liv Hospital. Explore advanced biomarker testing genomic sequencing and personalized oncology care.
Send us all your questions or requests, and our expert team will assist you.
Diagnosis and Staging
The diagnostic journey always begins with a deeply thorough clinical consultation and a highly detailed physical examination. When a patient arrives at Liv Hospital with suspicious physical symptoms our specialized oncologists conduct a meticulous review of their personal medical history and familial health background. This initial conversation provides crucial biological clues about the potential aggressiveness of the underlying cellular issue.
Following the initial interview the physician determines which specific diagnostic tests and imaging technologies are strictly required to visualize the internal structures safely. However unlike traditional medical diagnosis identifying the need for precision medicine requires looking far beyond the physical shape of the mass. The ultimate clinical goal is to extract the cellular tissue and analyze its deepest molecular architecture accurately to find actionable biological targets.
Biomarker testing is the absolute cornerstone of precision medicine acting as the definitive compass that guides the entire therapeutic journey safely. A biomarker is a highly specific biological molecule found in the blood other body fluids or deeply embedded within the tissue that acts as a definitive sign of an abnormal process or a specific disease. In precision oncology these biomarkers are typically unique genetic mutations or overactive cellular proteins.
The pathology laboratory utilizes advanced chemical stains and deep molecular analysis to evaluate the extracted tissue samples meticulously.
Testing the tissue to see if specific growth proteins are vastly overproduced.
Evaluating the cells for missing genetic repair mechanisms entirely.
Checking the molecular receptors located on the outer cellular membrane.
Identifying specific genetic translocations where DNA pieces have swapped places safely.
To truly understand the biological behavior of a highly aggressive mass specialists utilize an incredibly advanced laboratory technique known as next generation genomic sequencing. Rather than looking for one single known mutation at a time genomic sequencing rapidly analyzes millions of DNA strands simultaneously to create a complete highly detailed map of the entire tumor genome.
This staggering technological advancement allows the multidisciplinary tumor board to see the absolute complete genetic fingerprint of the disease. By reading the genetic code perfectly the medical team can pinpoint exactly which biological pathway the tumor relies on for its chaotic growth. This profound genetic insight is strictly required to match the patient with the absolute most effective highly targeted precision medication available globally.
In certain complex clinical scenarios physically extracting a tissue sample from a deep internal organ poses a highly significant physical risk to the patient. To overcome this massive biological hurdle modern oncology has developed a revolutionary diagnostic tool known clinically as a liquid biopsy. As abnormal cells divide and eventually die they naturally shed tiny microscopic fragments of their mutated DNA directly into the circulating bloodstream.
A liquid biopsy simply requires a standard routine blood draw securely taken from the patient arm. The highly specialized laboratory then isolates and deeply analyzes these microscopic fragments of circulating tumor DNA to identify the specific genetic mutations driving the disease. This incredibly safe minimally invasive test allows doctors to continuously monitor the genetic evolution of the tumor over time without requiring multiple traumatic surgical procedures safely.
When a liquid biopsy is insufficient or a larger physical tissue sample is strictly required for deep architectural analysis the surgeon performs a highly precise tissue biopsy securely. Using advanced real time ultrasound or computed tomography imaging for highly precise guidance the surgeon navigates a thin hollow needle directly into the core of the internal physical mass safely.
The safely extracted tissue samples are immediately preserved in specialized medical solutions and sent directly to the pathology department. This highly precise outpatient procedure is performed comfortably using excellent local anesthesia ensuring the mass is identified correctly without requiring a massive open surgical incision allowing the patient to completely return to the comfort of their own home the exact same day.
Receiving the highly complex genomic sequencing results can understandably cause significant anxiety for the patient and their supportive family. The detailed laboratory report outlines every single genetic anomaly discovered within the cellular DNA precisely. The primary oncology physician sits down quietly with the patient to transparently translate this highly technical biological data into a clear easily understandable clinical strategy safely.
If the report indicates a positive biomarker match it means the pathology team has successfully found a highly specific genetic target that can be actively attacked by an existing precision medication. If the tumor does not express any known targetable mutations the medical board will clearly explain alternative highly effective systemic therapies ensuring the patient receives the absolute best possible ongoing clinical care seamlessly.
While molecular profiling determines which specific drug to use clinical staging determines the exact physical extent of the disease heavily influencing the overall therapeutic timeline. Staging carefully evaluates the total physical size of the primary mass how deeply it has penetrated the local tissue wall and exactly how far the abnormal cells have traveled throughout the entire human circulatory and lymphatic systems securely.
The official clinical stages generally range from zero to four indicating the escalating severity of the biological spread perfectly.
Early stage localized disease may only require brief preventative precision medications safely.
Advanced stage disease with local lymph node spread requires aggressive prolonged intervention completely.
Metastatic stage four disease relies almost entirely on continuous targeted therapies for long term control securely.
Accurate staging ensures the medical board applies the precision drugs at the absolute optimal moment highly effectively.
Diagnosing and planning the highly complex targeted treatment for these specific conditions requires the collaborative expertise of multiple medical disciplines working together seamlessly. At Liv Hospital every single complex patient case is presented to a specialized multidisciplinary tumor board for a highly comprehensive collaborative review before any precision medication is officially prescribed securely.
This highly collaborative team includes expert surgical oncologists radiation specialists dedicated specialized radiologists and highly experienced molecular pathologists entirely. By reviewing the imaging scans liquid biopsy results and genetic profiles collectively the board members share their unique clinical perspectives ensuring that every possible therapeutic angle is deeply considered for maximum patient safety and absolutely optimal long term precision outcomes securely.
Send us all your questions or requests, and our expert team will assist you.
No a highly advanced liquid biopsy utilizes the exact same simple needle insertion process as a standard routine blood draw feeling completely identical and perfectly safe.
Next-Generation Sequencing (NGS) is a technology that enables doctors to scan a tumor’s DNA for mutations in hundreds of genes simultaneously, rather than testing them one by one. This provides a comprehensive “genetic fingerprint” of the cancer, revealing multiple potential treatment targets and helping identify rare mutations for which therapies are available.
Cancers can evolve and change over time, especially after exposure to treatment. The genetic mutations driving the tumor when it returns (recurrence) might be different from when it was first diagnosed. A new biopsy allows doctors to analyze the tumor’s current genetic profile to determine whether new targets have emerged or resistance mutations have developed.
“Wild Type” refers to a gene that does not have mutations; it is the standard, natural version of the gene. For example, if a tumor is “KRAS Wild Type,” it means the KRAS gene is normal. This is often good news for specific treatments (like EGFR inhibitors in colon cancer), which only work if KRAS is normal (Wild Type).
Liquid biopsy is becoming increasingly powerful, but it has not yet entirely replaced tissue biopsy. While it is excellent for detecting mutations and monitoring treatment, a tissue biopsy is often still needed for the initial diagnosis to examine the cells’ shape and structure (histology) and to obtain enough material for extensive testing if the amount of DNA in the blood is too low.
BlogCancerFeb 19, 2026Many people can live with stage 4 cancer for months without obvious signs. Advanced cancers often cause vag...
BlogCancerFeb 19, 2026Breast cancer diagnosis and treatment rely on specific tumor markers. At Liv Hospital, we focus on three ke...
BlogCancerFeb 19, 2026Explore ivermectin cancer clinical trials. Get amazing news on scary treatments and find powerful, vital ho...
BlogCancerFeb 19, 2026When chemotherapy stops working for multiple myeloma, patients face a tough challenge. The disease starts t...
BlogCancerFeb 18, 2026Neuroendocrine tumors (NETs) have long been tough to treat. But, new hope has arrived with the FDA’s ...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 510 71 24
